Lifesci Capital Forecasts iBio’s Q4 Earnings (NASDAQ:IBIO)

iBio, Inc. (NASDAQ:IBIO) – Equities research analysts at Lifesci Capital raised their Q4 2026 earnings estimates for shares of iBio in a research note issued on Wednesday, May 13th. Lifesci Capital analyst P. Dolezal now forecasts that the company will post earnings of ($0.06) per share for the quarter, up from their previous estimate of ($0.07). The consensus estimate for iBio’s current full-year earnings is ($0.32) per share. Lifesci Capital also issued estimates for iBio’s Q1 2027 earnings at ($0.06) EPS and Q2 2027 earnings at ($0.06) EPS.

A number of other equities analysts have also issued reports on the company. Wall Street Zen upgraded iBio from a “sell” rating to a “hold” rating in a research note on Saturday, April 4th. JonesTrading started coverage on iBio in a research note on Tuesday, March 3rd. They set a “buy” rating and a $7.00 price target on the stock. Chardan Capital reissued a “buy” rating and issued a $5.00 price objective on shares of iBio in a report on Thursday, April 9th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of iBio in a research note on Friday, March 27th. Three analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, iBio currently has an average rating of “Buy” and a consensus price target of $4.75.

iBio Price Performance

Shares of IBIO opened at $1.56 on Friday. The firm has a market capitalization of $56.38 million, a PE ratio of -2.69 and a beta of 1.23. iBio has a 1-year low of $0.56 and a 1-year high of $3.82. The company’s fifty day moving average price is $2.03 and its 200-day moving average price is $1.96.

iBio (NASDAQ:IBIO) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.01).

Hedge Funds Weigh In On iBio

A number of institutional investors have recently modified their holdings of IBIO. Geode Capital Management LLC boosted its stake in shares of iBio by 47.1% in the fourth quarter. Geode Capital Management LLC now owns 222,610 shares of the company’s stock worth $430,000 after buying an additional 71,301 shares during the last quarter. Ameriprise Financial Inc. acquired a new position in iBio in the third quarter valued at approximately $399,000. Cubist Systematic Strategies LLC acquired a new position in iBio in the first quarter valued at approximately $224,000. Boothbay Fund Management LLC boosted its position in iBio by 10.9% in the 3rd quarter. Boothbay Fund Management LLC now owns 176,862 shares of the company’s stock worth $146,000 after purchasing an additional 17,414 shares in the last quarter. Finally, State Street Corp grew its stake in shares of iBio by 116.3% during the 4th quarter. State Street Corp now owns 72,899 shares of the company’s stock worth $141,000 after purchasing an additional 39,200 shares during the period. Hedge funds and other institutional investors own 7.90% of the company’s stock.

Insider Activity

In other iBio news, CFO Felipe Duran bought 24,835 shares of the firm’s stock in a transaction that occurred on Thursday, March 19th. The stock was bought at an average cost of $2.02 per share, for a total transaction of $50,166.70. Following the completion of the transaction, the chief financial officer directly owned 35,974 shares of the company’s stock, valued at approximately $72,667.48. This trade represents a 222.96% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 2.75% of the stock is currently owned by company insiders.

iBio Company Profile

iBio, Inc, a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever.